GNKS-356

N/A

Report date: 2022/08/23 20:00:44
NME

Base Information

Drug NameGNKS-356
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionToll like receptor 9 antagonists
TargetsToll like receptor 9
Therapy Area/IndicationsPsoriasisLupus Erythematosus, SystemicInflammatory Bowel Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSbi Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSbi Biotech Co Ltd
Active IndicationsN/A
Inactive IndicationsPsoriasisLupus Erythematosus, SystemicInflammatory Bowel Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A